Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antioxidants/Cancer Health Claim Contradicted By ATBC Study - FDA

This article was originally published in The Tan Sheet

Executive Summary

Analyses from the 1994 Alpha-Tocopherol, Beta Carotene intervention trial raise "serious questions" about vitamin E's role in modifying cancer risk, FDA's Center for Food Safety & Applied Nutrition concludes May 4 in rejecting an antioxidant vitamins/cancer health claim.

You may also be interested in...



Research & Development In Brief: smokers and beta carotene; PUFA-enriched formula; antioxidants no boost for conception; vitamin D misses on blood pressure

Smokers’ beta carotene-mortality connection explored; PUFA-enriched infant formula speeds processing; antioxidants do not boost conception chances; and vitamin D does not lower blood pressure.

Research & Development In Brief: smokers and beta carotene; PUFA-enriched formula; antioxidants no boost for conception; vitamin D misses on blood pressure

Smokers’ beta carotene-mortality connection explored; PUFA-enriched infant formula speeds processing; antioxidants do not boost conception chances; and vitamin D does not lower blood pressure.

Beta Carotene Linked With Decreased Adenoma Recurrence In Nonsmokers

Beta carotene supplementation helps prevent colorectal adenoma recurrence in patients that do not smoke or consume high levels of alcohol, according to a study in the May 21 Journal of the National Cancer Institute

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel